Serious adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Proportion of people with adverse events · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes proportion of people with adverse events compared with placebo (very low certainty).
1 finding from 1 review
Number of adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with primary sclerosing cholangitis
1 finding from 1 review
Liver transplantation · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes liver transplantation compared with placebo (very low certainty).
1 finding from 1 review
Malignancy · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cholangiocarcinoma · people with primary sclerosing cholangitis
It is very uncertain whether ursodeoxycholic acid changes cholangiocarcinoma compared with placebo (very low certainty).
1 finding from 1 review
Colorectal cancer · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Short‐term mortality · people with acute pancreatitis
It is very uncertain whether the intervention changes short‐term mortality (very low certainty).
1 finding from 1 review
Intervention not reported
Long‐term mortality · people with acute pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events (proportion) · people with acute pancreatitis
It is very uncertain whether the intervention changes serious adverse events (proportion) (very low certainty).
1 finding from 1 review
Intervention not reported
Serious adverse events (number) · people with acute pancreatitis
1 finding from 1 review
Intervention not reported
Organ failure · people with acute pancreatitis
It is very uncertain whether the intervention changes organ failure (very low certainty).
1 finding from 1 review
Intervention not reported
Infected pancreatic necrosis · people with acute pancreatitis
It is very uncertain whether the intervention changes infected pancreatic necrosis (very low certainty).
1 finding from 1 review
Intervention not reported
Sepsis · people with acute pancreatitis
It is very uncertain whether the intervention changes sepsis (very low certainty).
1 finding from 1 review
Intervention not reported
Health‐related quality of life · people with acute pancreatitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (proportion) · people with non‐alcohol‐related fatty liver disease (NAFLD)
1 finding from 1 review
Serious adverse events (number of events) · people with non‐alcohol‐related fatty liver disease (NAFLD)
It is very uncertain whether thiazolidinediones changes serious adverse events (number of events) compared with no intervention (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with non‐alcohol‐related fatty liver disease (NAFLD)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found